News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
819,384 Results
Type
Article (84938)
Company Profile (620)
Press Release (733826)
Section
Business (231075)
Career Advice (4067)
Deals (39604)
Drug Delivery (102)
Drug Development (90207)
Employer Resources (192)
FDA (17769)
Job Trends (17219)
News (393395)
Policy (39537)
Tag
Academia (2967)
Africa (1259)
Alabama (32)
Allergies (41)
Alliances (56201)
Alzheimer's disease (1191)
Antibody-drug conjugate (ADC) (58)
Approvals (17716)
Arizona (186)
Artificial intelligence (55)
Asia (48732)
Australia (8574)
Bankruptcy (392)
Best Places to Work (12144)
Biosimilars (62)
C2C Services and Suppliers (95129)
California (763)
Canada (613)
Cancer (198)
Career advice (3482)
CAR-T (44)
Cell therapy (82)
China (42)
Clinical research (69764)
Collaboration (59)
COVID-19 (2714)
Cystic fibrosis (73)
Diabetes (34)
Diagnostics (6397)
Diversity, equity & inclusion (48)
Drug pricing (58)
Earnings (92533)
Employer resources (160)
Europe (111396)
Events (123996)
FDA (17802)
Florida (92)
Funding (40)
Gene therapy (62)
GLP-1 (556)
Government (4973)
Healthcare (20532)
Hotbed/Location (534692)
Idaho (62)
Illinois (238)
Indiana (107)
Infectious disease (2726)
Inflammatory bowel disease (94)
Interviews (804)
IPO (17401)
Job creations (5170)
Job search strategy (2846)
Kansas (96)
Layoffs (442)
Legal (9989)
Liver cancer (57)
Lung cancer (46)
Maine (51)
Management (59)
Manufacturing (56)
Maryland (261)
Massachusetts (436)
Medical device (14138)
Medtech (14141)
Mergers & acquisitions (21852)
Metabolic disorders (180)
Neuroscience (1280)
New Jersey (42)
New York (63)
NextGen Class of 2024 (7616)
Non-profit (5029)
North Carolina (173)
Obesity (114)
Opinion (221)
Parkinson's disease (32)
Patents (36)
Peanut (37)
Pennsylvania (35)
People (63357)
Phase I (21441)
Phase II (30293)
Phase III (22896)
Podcasts (64)
Policy (39)
Postmarket research (3529)
Preclinical (9721)
Rare diseases (92)
Real estate (7357)
Recruiting (72)
Regulatory (25371)
Reports (40)
Research institute (2622)
Resumes & cover letters (642)
South America (1641)
Startups (4259)
Texas (75)
United States (2934)
Vaccines (495)
Washington State (110)
Weight loss (119)
Date
Today (50)
Last 7 days (366)
Last 30 days (1609)
Last 365 days (40759)
2024 (23041)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51342)
2018 (39126)
2017 (37194)
2016 (38330)
2015 (44435)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
819,384 Results for "121 bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
June 18, 2024
·
9 min read
Drug Development
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prostate cancer (mCRPC).
June 5, 2024
·
1 min read
Pharm Country
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
Intelligent Bio Solutions Inc. today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024.
June 6, 2024
·
1 min read
Amgen-Backed Seismic Secures $121M in Series B Funding
Mass.-based Seismic Therapeutic secured a new investor in Bessemer Venture Partners and $121 million in its Series B round as it looks to push its two lead candidates into the clinic.
December 4, 2023
·
2 min read
·
Tyler Patchen
Drug Development
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
REGENXBIO Inc. (Nasdaq: RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II) demonstrating that the pivotal phase of the trial met its primary endpoint with statistical significance.
February 7, 2024
·
10 min read
BioMidwest
Aruna Bio to Present at BIO International Convention 2024
Aruna Bio, Inc. announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the 2024 BIO International Convention being held June 3-6, 2024 at the San Diego Convention Center, California.
May 28, 2024
·
1 min read
Collaboration
Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
July 25, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention
BlueSphere Bio today announced that Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio, will provide a corporate update and participate in a panel discussion at the 2024 BIO International convention being held from June 3 – 6, 2024.
May 30, 2024
·
3 min read
Lone Star Bio
Matica Bio at BIO International 2024: Leading the Way in CGT Innovation and U.S. Manufacturing Strategy
Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).
May 22, 2024
·
4 min read
Biotech Beach
GRI Bio to Present at the 8th Annual IPF Summit
GRI Bio, Inc. today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.
July 1, 2024
·
4 min read
1 of 81,939
Next